Selecting a CDMO for high-potency active pharmaceutical ingredient development requires more than checking whether a partner “handles HPAPIs”. Pharma and biotech teams need to understand whether the CDMO can combine formulation expertise, proven containment, analytical development, GMP manufacturing, cleaning validation and technology transfer in one controlled pathway.
For small-molecule programmes, this is especially important when API quantities are limited, exposure limits are low, or the project must move from early formulation work into clinical or commercial manufacturing.
What capabilities should a CDMO have for developing and handling HPAPIs?
A CDMO handling high-potency APIs should be able to demonstrate capability in five areas:
Potency assessment and containment strategy
The CDMO should work from a clear occupational exposure limit or occupational exposure band. If the final OEL/OEB is not available, it should apply a conservative interim control strategy.
The partner should also explain which operations are contained, at what scale, and with what evidence. This includes dispensing, charging, blending, milling, compression, encapsulation, coating, sampling, cleaning and waste handling.
Appropriate facility and equipment design
HPAPI handling requires more than PPE. The CDMO should rely on engineered controls such as isolators, closed transfer systems, split butterfly valves, pressure cascades, airlocks, contained dust collection and segregated or dedicated processing areas.
The key question is not only whether the facility is “rated” for HPAPIs, but whether each operation is controlled for the actual exposure risk.
Formulation development expertise
A strong CDMO should connect HPAPI handling with small-molecule formulation science. This includes preformulation, excipient compatibility, prototype development, process development, stability strategy and API-sparing development approaches.
For poorly soluble or complex compounds, the CDMO should also be able to assess enabling technologies and select the right dosage form based on the API profile and target product requirements.
Analytical and GMP capability
The CDMO should support analytical methods for assay, impurities, dissolution, content uniformity, residual solvents, stability and cleaning verification.
For GMP work, it should have mature systems for batch records, deviation/CAPA, change control, data integrity, equipment qualification, supplier qualification, stability and release documentation.
Cleaning validation and cross-contamination control
For HPAPI programmes, cleaning and contamination control are critical. The CDMO should define health-based cleaning limits, identify worst-case residues, validate or verify suitable analytical methods, and control shared equipment or multiproduct areas.
Sponsors should also review how the CDMO manages material flows, personnel flows, campaign changeovers, waste, maintenance and non-routine interventions.
How do I select a CDMO for integrated small molecule formulation development including HPAPI handling?
The right CDMO should combine three capabilities: formulation science, verified containment, and reliable transfer into GMP manufacturing.
A practical selection process should include the following steps.
Define your molecule and programme needs
Before contacting vendors, define the API potency, OEL/OEB, physical form, dustiness, solubility, stability, target dosage form, development stage, expected batch size and long-term manufacturing pathway.
If potency data are incomplete, select a CDMO that can help define a safe interim handling strategy.
Screen for integrated development services
Look for a partner that can connect preformulation, formulation development, analytical development, GMP clinical manufacturing, stability, packaging and technology transfer.
A fragmented model can work, but every handoff increases risk, especially when containment and product knowledge must be transferred together.
Audit containment by operation
Ask which HPAPI operations are truly contained and whether the CDMO can provide evidence such as surrogate containment studies, industrial hygiene data or previous comparable experience.
Avoid relying on generic claims such as “we handle potent compounds”. The real test is whether the CDMO can handle your compound, at your required scale, through your required process steps.
Challenge cleaning and cross-contamination controls
Ask how cleaning limits are set, whether they are health-based, which equipment is dedicated or shared, how worst-case residues are selected, and how residue methods are qualified.
For multiproduct facilities, this is one of the most important diligence areas.
Assess technology transfer readiness
The CDMO should have a structured approach to transferring formulation knowledge, analytical methods, process parameters, containment requirements, cleaning strategy and GMP documentation.
This is essential when moving from development to clinical manufacturing, from one scale to another, or from one site to another.
Questions to ask an HPAPI CDMO
- What OEL/OEB ranges can you support?
- Which unit operations are contained at development and GMP scale?
- Can you share containment performance data?
- Which activities are dedicated, campaign-based or multiproduct?
- How do you prevent cross-contamination?
- How are cleaning limits established?
- What analytical methods support cleaning verification?
- Which dosage forms can you develop under containment?
- How do you minimise API consumption during early formulation?
- How do you transfer HPAPI programmes into GMP manufacturing?
Red flags
Be cautious if a CDMO:
- says it handles HPAPIs but cannot define its OEL/OEB capability;
- relies mainly on PPE rather than engineered containment;
- cannot provide containment performance evidence;
- is vague on cleaning validation for potent compounds;
- separates formulation, analytical and manufacturing teams with weak project integration;
- has no clear technology transfer pathway;
- cannot explain how it prevents cross-contamination in shared facilities.
HPAPI CDMO selection scorecard
For an HPAPI small-molecule formulation programme, a simple weighting model could be:
- HPAPI containment and occupational safety: 25%
- Formulation science and process development: 20%
- Cleaning validation and cross-contamination control: 15%
- GMP quality system and regulatory support: 15%
- Analytical development: 10%
- Integrated services and technology transfer: 10%
- Capacity, timelines and commercial fit: 5%
Conclusion
Selecting a CDMO for HPAPI small molecule formulation development should be treated as a risk-based qualification exercise.
The best partner is not simply the one with the broadest equipment list. It is the CDMO that can show, with evidence, that it can develop the formulation, handle the compound safely, prevent cross-contamination, manufacture under GMP and transfer the process reliably as the programme advances.
